The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
TMPRSS2 : ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis
Abstract
Purpose: Our aim was to assess the frequency of ERG overexpression and TMPRSS2:ERG rearrangement in prostate cancer and their association with clinicopathologic variables and outcome. Experimental Design: The presence of the TMPRSS2:ERG rearrangement was studied by reverse transcription-PCR and fluorescence in situ hybridization in 19 prostate cancer xenografts and 7 prostate cancer cell lines. The expression of ERG was studied in the xenografts and cell lines and in 49 freshly frozen clinical prostate samples by quantitative reverse transcription-PCR. The frequency of the TMPRSS2:ERG fusion in clinical prostate cancer (n = 253) on tissue microarrays was assessed by three-color fluorescence in situ hybridization. Results: Seven of 19 (37%) of the xenografts overexpressed ERG and had TMPRSS2:ERG rearrangement. Two xenografts, representing small cell carcinomas, also contained the fusion but did not express ERG. In clinical tumor specimens, the overexpression of ERG was associated with the rearrangement (P = 0.0019). Fifty of 150 (33%) of the prostatectomy specimens and 28 of 76 (37%) of the hormone-refractory prostate cancers on the tissue microarrays carried the TMPRSS2:ERG rearrangement. It was associated with longer progression-free survival in patients treated by prostatectomy (P = 0.019), and according to multivariate analysis, it was an independent predictor of favorable outcome (relative risk, 0.54; 95% confidence interval, 0.30-0.98). The fusion was not associated with Gleason score, pT stage, diagnostic prostate-specific antigen, or cell proliferation activity in prostatectomy specimens nor with the AR gene amplification in hormone-refractory tumors. Conclusions: The TMPRSS2:ERG rearrangement can be found in about one third of prostate cancers. A subgroup of prostate cancer patients with a good prognosis may be identified by the rearrangement.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Cited by
Molecular genetics of prostate cancer: new prospects for old challenges
Shen, M. M., & Abate-Shen, C. (2010) · Genes & Development · doi:10.1101/gad.1965810 · Cited by 946
A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer
The Breast and Prostate Cancer Cohort Consortium (BPC3), Al Olama, A. A., The PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium, The COGS (Collaborative Oncological Gene-environment Study) Consortium, The GAME-ON/ELLIPSE Consortium, Kote-Jarai, Z., Berndt, S. I., Conti, D. V., Schumacher, F., Han, Y., et al. (2014) · Nature Genetics · doi:10.1038/ng.3094 · Cited by 455
Self-citationETS Gene Fusions in Prostate Cancer: From Discovery to Daily Clinical Practice
Tomlins, S. A., Bjartell, A., Chinnaiyan, A. M., Jenster, G., Nam, R. K., Rubin, M. A., & Schalken, J. A. (2009) · European Urology · doi:10.1016/j.eururo.2009.04.036 · Cited by 381
Leyten, G. H. J. M., Hessels, D., Jannink, S. A., Smit, F. P., de Jong, H., Cornel, E. B., de Reijke, T. M., Vergunst, H., Kil, P., Knipscheer, B. C., et al. (2014) · European Urology · doi:10.1016/j.eururo.2012.11.014 · Cited by 352
Pettersson, A., Graff, R. E., Bauer, S. R., Pitt, M. J., Lis, R. T., Stack, E. C., Martin, N. E., Kunz, L., Penney, K. L., Ligon, A. H., et al. (2012) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-12-0042 · Cited by 319
Metadata
- Authors
- Saramäki, O. R., Harjula, A. E., Martikainen, P. M., Vessella, R. L., Tammela, T. L. J., & Visakorpi, T.
- Venue
- Clinical Cancer Research
- Published
- 2008-06-01
- Volume
- 14
- Issue
- 11
- Pages
- 3395-3400
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W1998076166
- Cited by
- 243
- References
- 1
- FWCI
- 20.87
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: TMPRSS2 : ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-07-2051
- The paper
- Saramäki, O. R., Harjula, A. E., Martikainen, P. M., Vessella, R. L., Tammela, T. L. J., & Visakorpi, T. (2008). TMPRSS2 : ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-07-2051
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.